ACPE Accreditation

ACPE Continuing Pharmacy Education
This program has been planned and implemented in accordance with the policies of the Accreditation Council on Pharmacy Education (ACPE) through the joint sponsorship of the Oregon State University College of Pharmacy and the Oregon Society of Health-System Pharmacists (OSHP). The Oregon State University College of Pharmacy is accredited by the Accreditation Council on Pharmacy Education as a provider of continuing pharmacy education. 

Pharmacists and Pharmacy Technicians will receive ACPE Continuing Education Credit. An NABP e-Profile ID is required to receive CPE hours. An NABP e-Profile ID can be obtained at MyCPEMonitor.net. Statement of Credit shall be issued only after successful completion of the program. Successful completion is defined as: 1) Attending, in its entirety, the CPE activity or activities; 2) Participation in the pre-test administered by the presenter; 3) Completion of the online activity evaluation and post-test located at: http://pharmacy.oregonstate.edu/ce within 14 days of program attendance. 

Statements of Credit will be uploaded to each participant’s NABP e-profile automatically within 48 hours of successful program completion. It is the participant’s responsibility to complete the online components within 14 days of program attendance to ensure awarding of credit. It is the participant's responsibility to check CPE Monitor and ensure credits have successfully uploaded. 

Target Audience: Pharmacists and Pharmacy Technicians
Total Credits Available: 5.25 hours (0.525 CEUs)
Conflict of Interest Disclosures: Dr. Kendall J. Tucker has received grant funded research from Merck. This financial relationship has been mitigated. No other speakers or planners for this program have any financial relationships with ineligible companies to disclose. 

Title: Halfway Broken or Stuck in Neutral: Pharmacological and Nonpharmacological Options for HFmrEF/HFpEF
UAN: 0036-9999-25-216-L01-P and 0036-9999-25-217-L01-T
Date & Time: 11/15/25, 8:00-9:15 am,
Speakers: Harleen Singh, PharmD, BCACP, UTEP
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Credit Hours: 1.25 (0.125 CEUs)

RPh Learning Objectives:

  1. Outline a concise overview of current management guidelines for HFmrEF and HFpEF
  2. Interpret and critique recent clinical trial results on emerging therapies for HFmrEF and HFpEF
  3. Integrate nonpharmacological interventions into patient centered plans
  4. Apply evidence-based recommendations in patient case discussions to optimize individualized management strategies for HFmrEF and HFpEF

CPT Learning Objectives:

  1. Outline a concise overview of current management guidelines for HFmrEF and HFpEF
  2. Interpret and critique recent clinical trial results on emerging therapies for HFmrEF and HFpEF
  3. Discuss nonpharmacological interventions and how they might be used in patient centered plans 

Title: Complicated Urinary Tract Infections: Updates in Guidelines and Pharmacist Roles
UAN: 0036-9999-25-218-L01-P and 0036-9999-25-219-L01-T
Date & Time: 11/15/25, 9:35-10:05 am
Speakers: Kendall J. Tucker, PharmD, MS, BCPS, BCIDP, Oregon State University College of Pharmacy, Clinical Assistant Professor
Activity-Type: Application-based for RPh; Knowledge-based for CPT
Credit Hours: 0.5 (0.05 CEUs)

RPH Learning Objectives:

  1. Explain updated guideline classifications for the treatment of complicated urinary tract infections
  2. Discuss evidence-based options for initial and definitive selection of antibiotics for complicated UTI
  3. Given a patient scenario, recommend the best pharmacologic treatment for cUTI

CPT Learning Objectives:

  1. Explain updated guideline classifications for the treatment of complicated urinary tract infections
  2. Recognize the options for initial and definitive selection of antibiotics for complicated UTI
  3. Identify key elements of pharmacologic treatment for cUTI

Title: Beyond Blood Sugars: GLP-1s in Heart Failure with Preserved Ejection Fraction
UAN: 0036-9999-25-220-L01-P/T
Date & Time: 11/15/25, 10:05-10:35 am
Speakers: Savannah Hiebel, PharmD, Kaiser Permanente, PGY1 Pharmacy Resident; Ellie Howie, PharmD, RPh, Kaiser Permanente, PGY1 Pharmacy Resident
Activity-Type: Knowledge-based
Credit Hours: 0.5 (0.05 CEUs)

RPH Learning Objectives:

  1. Describe the pathophysiology of HFpEF and the role of cardiometabolic comorbidities such as obesity and type 2 diabetes
  2. Explain the mechanisms of actions of GLP-1 RAs and how they may benefit patients with HFpEF
  3. Summarize key clinical trial data supporting the use of GLP-1 RAs (e.g., STEP-HFpEF, SUMMIT, real-world evidence)
  4. Evaluate the potential benefits and risks of GLP-1 RAs in HFpEF, including their impact of hospitalization, mortality, and quality of life
  5. Discuss the implications for clinical practice, including patient selection and integration with existing HFpEF therapies like SGLT2 inhibitors

CPT Learning Objectives:

  1. Identify common GLP-1 receptor agonists used in patients with HFpEF, including brand/generic names and therapeutic class
  2. Recognize key safety considerations for GLP-1 RAs, including high-alert status, storage requirements, and common side effects
  3. Describe proper handling and administration instructions for GLP-1 RAs, including injection technique and patient counseling points
  4. Support collaborative workflows with pharmacists and healthcare teams in managing GLP-1 RA therapy for HFpEF patients

Title: Guts and Butts: New and Novel Therapeutics for Management of Chronic Idiopathic Constipation and Inflammatory Bowel Disease
UAN: 0036-9999-25-221-L01-P/T
Date & Time: 11/15/25, 2:00-3:00 pm
Speakers: Jenny Rubinstein, PharmD, CSP, OHSU, Adult Gastroenterology/Inflammatory Bowel Disease Clinical Pharmacist
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)

Learning Objectives:

  1. Explain how therapeutics can be used in management of inflammatory bowel disease (IBD) with an emphasis on advanced therapies and targeted therapeutics for chronic idiopathic constipation (CIC)
  2. Evaluate current guidelines and evidence to help determine agent selection for management of IBD and CIC
  3. Recall practical ways to best care for complex GI cases in a real-world setting 

Title: Introduction to Trauma Informed Care: Theory and Practice
UAN: 0036-9999-25-222-L99-P/T
Date & Time: 11/15/25, 3:00-4:00 pm
Speakers: Ian Alexander, BA, OHSU, Social Work Specialist; Carissa Williams, LCSW, MPH, OHSU, Clinical Outreach Social Worker
Activity-Type: Knowledge-based
Credit Hours: 1.0 (0.1 CEUs)
State Requirement: Cultural Competence

Learning Objectives:

  1. Define the 3 E’s of trauma informed care
  2. Explain the benefits of providing trauma informed care
  3. Discuss the core principles of trauma informed care
  4. Review how healthcare providers can help patients address trauma